A Phase 1, Open-label Study In Healthy Subjects To Evaluate The Pharmacokinetics Of Pf-06882961 Following Single Oral Administration Of Immediate Release Tablets And An Immediate Release Oral Solution In The Fed State, And Controlled Release Tablets In The Fed And Fasted States
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2018
Price : $35 *
At a glance
- Drugs PF-06882961 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Pfizer
- 27 Jul 2018 Status changed from recruiting to completed.
- 03 May 2018 Status changed from not yet recruiting to recruiting.
- 12 Apr 2018 New trial record